CBD and GLP-1 Weight-Loss Drugs: What Users Need to Know About Safety

More than 12% of U.S. adults have used a GLP-1 receptor agonist like Ozempic, Wegovy, or Mounjaro, according to a 2024 KFF Health Tracking Poll, and a growing share of those same users also take CBD for sleep, anxiety, or chronic pain. The question of whether CBD and GLP-1 medications interact safely has moved from a niche curiosity to a routine pharmacy counter conversation. Real-world evidence is still thin, but pharmacology gives us enough to sketch the actual risks.

This article walks through what the science currently says about combining CBD and GLP-1 receptor agonists. You’ll find sections on the CYP450 metabolism question, the overlapping problem of slowed gastric emptying, side-effect stacking, dosing considerations, and what to ask your doctor. Each claim is sourced to FDA prescribing information, peer-reviewed research, or major academic medical centers.

The short version: the interaction picture is more nuanced than the alarmist headlines suggest, but it’s also not nothing. A few specific risks deserve attention.

Understanding GLP-1 Receptor Agonists

GLP-1 receptor agonists are injectable medications that mimic glucagon-like peptide-1, a gut hormone the body releases after eating. They were originally approved for type 2 diabetes, then rapidly expanded into weight management once the trial data made the appetite-suppressing effect impossible to ignore. The class works through several mechanisms at once, which is part of why side effects can be unpredictable from person to person.

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases describes GLP-1 agonists as one of the most effective medical tools currently available for sustained weight loss, with average reductions of 15% or more of body weight in the key registration trial, per the STEP 1 trial published in the New England Journal of Medicine in 2021. That kind of efficacy has driven a roughly 700% increase in prescriptions between 2019 and 2023, according to analyses of pharmacy claims data.

The Main Drugs in This Class

Several GLP-1 receptor agonists are currently on the market, and the names you’ll hear most often come down to three molecules sold under different brand names for different uses. Semaglutide is marketed as Ozempic for type 2 diabetes and as Wegovy for chronic weight management, per the FDA prescribing information for Ozempic. Tirzepatide, a dual GIP/GLP-1 agonist, is sold as Mounjaro for diabetes and Zepbound for weight loss.

Liraglutide, an older daily-injection version, is sold as Victoza and Saxenda. There are also a handful of oral options, including oral semaglutide marketed as Rybelsus. The injectable weekly versions have become the dominant form because of convenience, and the bulk of safety data on CBD and GLP-1 co-use comes from people on those weekly injections.

How These Drugs Actually Work

GLP-1 agonists do three main things. They stimulate insulin release when blood sugar is high, they suppress glucagon, and they slow how fast the stomach empties food into the small intestine. That last effect, called delayed gastric emptying, is the one that drives both the appetite suppression and most of the unpleasant GI side effects, per the Wegovy prescribing information from the FDA.

Here’s the part that matters most for our discussion: these molecules are peptides. Your liver’s cytochrome P450 enzyme system, which breaks down most small-molecule drugs and is the main place CBD causes interactions, doesn’t process them in a meaningful way. They’re cleared by general proteolysis throughout the body. That single biochemical fact reshapes the whole conversation about CBD and GLP-1 interactions, as we’ll see in the next section.

CBD and GLP-1: What the Pharmacology Actually Says

Cannabidiol has a well-documented effect on liver enzymes, particularly CYP3A4, CYP2C9, CYP2C19, and CYP2D6. The FDA’s approval label for Epidiolex, the only FDA-approved CBD drug, explicitly warns about these interactions, per the Epidiolex prescribing information. A 2019 review by Brown and Winterstein in the Journal of Clinical Medicine mapped out more than 50 medications with potential CBD interactions through those enzymes.

Here’s where the headline-grabbing fear collides with the actual chemistry. Because GLP-1 drugs are peptides cleared by proteolysis, the CYP450 enzyme question doesn’t apply to them the way it does to, say, warfarin or statins. The current pharmacology literature does not show direct CYP-mediated interactions between CBD and semaglutide, tirzepatide, or liraglutide.

That’s the good news. The complication is that most people on GLP-1 medications take other drugs too, and several of those, blood thinners, certain statins, some antidepressants, and various seizure medications, do interact with CBD through CYP450. So the CBD and GLP-1 conversation often becomes a CBD plus other-medications conversation by default.

The Gastric Emptying Overlap

This is where the more interesting interaction lives. GLP-1 agonists dramatically slow gastric emptying, and that’s the main mechanism behind their satiety effect. CBD also influences gastrointestinal motility, though the picture is messier. A 2017 review in Cannabis and Cannabinoid Research describes how cannabinoids interact with CB1 and CB2 receptors in the gut, generally trending toward slowed motility and reduced GI contractions.

So you have two substances that, by different mechanisms, both tend to slow things down in the digestive tract. Stack them, and a meal that would normally sit comfortably can linger longer than it should. The clinical concern is that this could intensify nausea, early satiety, reflux, and bloating, the exact side effects most likely to drive people off GLP-1 therapy in the first place.

No published clinical trial has directly measured gastric emptying in people taking CBD and a GLP-1 drug at the same time. The risk is inferred from how each substance behaves on its own. That inference is reasonable enough that several pharmacy associations have begun flagging it as worth discussing with patients.

Anesthesia and Surgery Concerns

The American Society of Anesthesiologists issued guidance in 2023 recommending that patients pause GLP-1 medications before elective surgery because of the risk of food remaining in the stomach during anesthesia, per the ASA’s consensus-based guidance. The concern is pulmonary aspiration. CBD, in higher doses, may compound this delay, though the data here is limited to case reports rather than controlled trials.

If you take CBD and GLP-1 medications and have a procedure coming up, mention both to your anesthesiologist by name and brand. Don’t assume the pre-op checklist captures CBD, because in most hospitals it doesn’t.

Side Effects That Can Stack

The GI side effects of GLP-1 drugs are well-documented. According to the FDA label for Ozempic, the most common adverse events in clinical trials were nausea (16-20% of users), vomiting, diarrhea, constipation, abdominal pain, and dyspepsia. Most are mild to moderate and tend to fade after the first few weeks, but for some people they linger.

CBD’s adverse event profile, summarized in the 2018 World Health Organization CBD critical review, includes diarrhea, decreased appetite, fatigue, and changes in liver enzymes at higher doses. There’s measurable overlap with what GLP-1 drugs cause. The clinical question isn’t whether CBD makes you grow a new symptom, it’s whether it nudges an existing GLP-1 side effect from tolerable into miserable.

The side effects most likely to stack are listed below, and they’re worth tracking if you start CBD while already on a GLP-1 drug, or vice versa.

• Nausea: Already the top complaint with GLP-1 drugs. CBD doesn’t usually cause nausea on its own, but slowed gastric emptying from both substances may worsen it.
• Diarrhea: Listed as a side effect of both CBD and GLP-1 medications. Higher CBD doses are more likely to contribute.
• Decreased appetite: Both reduce appetite through different mechanisms. The combined effect could push some users into inadequate calorie or protein intake.
• Fatigue: A known CBD side effect; some GLP-1 users also report low energy, especially early in treatment.
• Liver enzyme elevations: Reported with high-dose CBD in the Epidiolex trials. Worth monitoring if you have any pre-existing liver concerns.

If side effects worsen after you add CBD, the practical move is to pause the CBD first and see if symptoms ease within a week. That’s an easier variable to control than the GLP-1 dose schedule.

Hypoglycemia With Insulin or Sulfonylureas

One subtle interaction worth flagging: GLP-1 agonists don’t usually cause low blood sugar on their own, but they can amplify the hypoglycemic effect of insulin or sulfonylureas like glipizide. CBD, separately, has shown modest effects on glucose regulation in small studies. People combining all three categories, a GLP-1 drug, a sulfonylurea or insulin, and CBD, should monitor blood glucose more often during the first weeks of any change.

This isn’t a reason to avoid CBD if you’re using a GLP-1 alone for weight management, since those patients usually aren’t on insulin or sulfonylureas. It’s a flag for people using GLP-1 drugs for type 2 diabetes alongside other glucose-lowering medications.

What the Research Says So Far

Direct human research on CBD and GLP-1 co-administration barely exists. There’s no randomized controlled trial of CBD added to semaglutide, tirzepatide, or liraglutide. What we have is a patchwork of indirect evidence, parallel studies on each drug class, and a small pile of case reports and pharmacovigilance signals.

Preclinical and Mechanistic Work

Animal research suggests cannabinoids can influence the same metabolic pathways that GLP-1 drugs target. A 2020 study in Frontiers in Endocrinology reviewed how the endocannabinoid system regulates appetite, glucose homeostasis, and energy balance, sometimes in ways that overlap with GLP-1 signaling. Early animal models hint at additive effects on food intake, though the translation to humans is far from settled.

On the gastric emptying side, controlled studies in healthy volunteers have shown that semaglutide can slow gastric emptying by 30% or more at therapeutic doses, per pharmacokinetic data summarized in the Ozempic prescribing information. CBD’s effect on human gastric emptying hasn’t been as cleanly quantified, but cannabinoid receptor activity in gut tissue is well-established.

Clinical and Real-World Signals

A growing body of survey research suggests that CBD use is common among adults using prescription medications generally. A 2022 cross-sectional study in JAMA Network Open found that more than one in five U.S. adults had used a CBD product in the prior year, with concurrent prescription medication use very common.

Case reports describing CBD interactions with specific drugs do exist, mostly involving warfarin, clobazam, and tacrolimus, all CYP450-metabolized. No published case reports clearly identify a CBD-GLP-1 adverse event as of mid-2025, but pharmacovigilance databases don’t usually capture supplements well, so the absence may reflect underreporting more than true safety.

Research Limitations

The biggest gap is the lack of any prospective study explicitly testing CBD and GLP-1 co-use. Sample sizes in CBD interaction research are usually small, often fewer than 100 participants, and CBD products in the consumer market vary widely in actual content, which makes generalization harder. Long-term safety data on GLP-1 drugs for weight loss in non-diabetic populations is also still accumulating.

Until interventional trials catch up, clinical guidance will continue to rest on pharmacology-based inference and the experience of clinicians managing patients in practice.

Practical Guidance for People Using Both

If you’re already using CBD and considering a GLP-1 drug, or already on a GLP-1 drug and thinking about adding CBD, a few practical steps lower the risk meaningfully. None of this is a substitute for talking to your prescriber, but it’s a reasonable starting framework.

Start by writing down everything you take, including CBD products with their concentrations and doses, and bring that list to your next appointment. Many people don’t disclose CBD use to their doctors because it isn’t asked about on intake forms, per a 2021 survey in Cannabis and Cannabinoid Research. That gap is part of why interaction signals get missed in the literature.

Timing and Dosing

If your clinician is comfortable with you using both, two simple adjustments help. First, separate CBD and GLP-1 medications in time when possible. GLP-1 weekly injections are absorbed regardless of timing, but oral CBD taken closer to meals may interact more with the gastric-emptying effect. Spacing CBD a few hours from your largest meals can reduce the chance of compounded nausea.

Second, start CBD at the lowest reasonable dose, often 10 to 25 mg of a verified product, and hold steady for at least a week before titrating up. Standard CBD dosing advice already favors a slow titration, but it’s especially relevant when you’re stacking it on a GLP-1, where any new GI symptom is hard to attribute cleanly.

What to Watch For

Keep a simple symptom log for the first two to four weeks after any change. Note nausea, reflux, fullness after small meals, bowel changes, fatigue, and appetite. If something worsens, the CBD is the easier variable to pause first. GLP-1 dosing follows a strict titration schedule, and skipping doses can disrupt blood sugar control or weight progress.

Get liver enzymes checked if you’re using both for more than a few months, especially at higher CBD doses. The Epidiolex trials saw elevations in ALT and AST in a meaningful minority of participants, and while typical wellness-CBD doses are far lower, baseline plus follow-up labs are cheap insurance.

What to Look for in a CBD Product

The CBD market is not FDA-regulated for over-the-counter wellness products, and independent testing routinely finds discrepancies between labeled and actual CBD content. A 2017 study published in JAMA tested 84 online CBD products and found that only about 31% were accurately labeled. The number has improved since, but consumers still need to read labels carefully.

For anyone combining CBD and GLP-1 medications, product quality matters more than usual. You want predictable dosing so any symptom changes can actually be attributed to the right cause. Look for the following signals on any CBD product you’re considering.

• Certificate of Analysis (COA): A current, batch-specific lab report from an independent third party. The COA should match the lot number on the bottle.
• Cannabinoid profile: Verified CBD content within 10% of the label claim, and THC content below the 0.3% legal threshold for hemp-derived products.
• Contaminant testing: Screening for pesticides, heavy metals, residual solvents, and microbial contamination.
• Extraction method: CO2 extraction is generally preferred because it avoids hydrocarbon solvent residues.
• Hemp source: U.S.-grown hemp from states with established agriculture programs offers more traceability than imported sources.

Avoid products that make specific medical claims, including weight loss claims, because the FDA has issued warning letters to companies marketing CBD with disease claims. A reputable brand will describe its product accurately and let the science speak for itself.

Frequently Asked Questions About CBD and GLP-1

Can I take CBD oil while on Ozempic or Wegovy?

There’s no absolute contraindication, but you should talk to your prescriber first. CBD and GLP-1 drugs don’t share a major metabolism pathway, so direct enzyme-level interactions are unlikely. The bigger concern is overlapping GI side effects and slowed gastric emptying. Many people use both without issue, while others find their GLP-1 side effects worsen when they add CBD. Start at a low CBD dose and track symptoms for the first few weeks.

Does CBD interfere with how Mounjaro or Zepbound work?

Current pharmacology doesn’t show CBD reducing the effectiveness of tirzepatide. Both Mounjaro and Zepbound are peptides cleared outside the cytochrome P450 system, the main place CBD causes drug interactions. The active glucose-lowering and appetite-suppressing effects of tirzepatide aren’t expected to be blunted by typical CBD doses, though long-term combined-use data is still limited.

Could CBD help with GLP-1 side effects like nausea?

There’s no good evidence that CBD reduces GLP-1-related nausea, and the mechanism actually points the other way. Both substances slow gastric emptying, which is the main driver of GLP-1 nausea. CBD’s antiemetic effect, where it exists, is most consistent for chemotherapy-induced nausea rather than gastroparesis-type symptoms. If GLP-1 nausea is severe, talk to your prescriber about dose adjustment rather than adding CBD.

Should I stop CBD before surgery if I’m on a GLP-1?

Yes, in most cases. The American Society of Anesthesiologists recommends pausing GLP-1 drugs before elective surgery due to delayed gastric emptying and aspiration risk. Adding CBD to that risk profile isn’t worth it for an elective procedure. A reasonable plan is to stop CBD at least 48 to 72 hours before surgery and tell your anesthesiologist about both products by name.

What about CBD gummies vs. CBD oil with GLP-1 drugs?

Edibles like gummies are absorbed through the digestive tract, so they’re more directly affected by slowed gastric emptying. Onset may be delayed and unpredictable when you’re on a GLP-1 drug. Sublingual CBD oils, held under the tongue, bypass much of the GI system and may give more predictable effects. Topical CBD products don’t reach meaningful blood levels and aren’t expected to interact with GLP-1 medications.

Conclusion

The honest answer about CBD and GLP-1 medications is that the strongest interaction concern isn’t the one most articles focus on. The cytochrome P450 question, while real for many drug pairs, doesn’t apply much to peptide-based GLP-1 agonists. The slowed gastric emptying overlap is more clinically relevant, especially in the first weeks of GLP-1 titration when nausea and reflux are already most likely. Side-effect stacking, particularly in the GI tract, is the practical risk to watch.

None of this means you can’t use CBD and GLP-1 drugs together. It means doing so with intention: a verified product, a low starting dose, a written symptom log, and an honest conversation with your prescriber. CBD is a meaningful tool for many people managing anxiety, sleep, and pain, and GLP-1 medications are a meaningful tool for diabetes and weight management. The two can coexist for most users, but the combination deserves more care than either alone.

The Bottom Line: Combining CBD and GLP-1 medications is generally low risk for drug-metabolism conflicts, but the overlap in slowed gastric emptying and GI side effects makes a low starting dose, careful symptom tracking, and a conversation with your prescriber the right approach.